Quell’s Treg platform induces sustained expression of FOXP3. Image credit: Shutterstock/ Vink Fan. AstraZeneca has exercised an option to license a cell therapy from Quell
Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) presents with symptoms primarily related to heart failure and impaired cardiac function. Credit: Rawpixel.com via Shutterstock. Intellia Therapeutics has announced
Good morning and welcome to another working week. We hope the weekend respite was refreshing and invigorating because — you know what we are going
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. It’s been a busy November here at
Afqlir is set to combat blindness associated with neovascular age-related macular degeneration. Credit: SG SHOT/Shutterstock. The European Commission (EC) has granted marketing authorisation for Sandoz‘s
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning! Today, we talk
The Food and Drug Administration approved on Friday a new drug developed by Syndax Pharmaceuticals to treat patients with a genetically defined form of advanced
Regenxbio reported Monday the first clinical evidence showing improved muscle function in boys with Duchenne muscular dystrophy following treatment with its experimental gene therapy. The
The MedTech industry is at the forefront of health care innovation, offering advanced medical devices crucial for accurate diagnoses, effective treatments and improved patient care.
Type 2 diabetes can lead to diabetic kidney disease, but a class of drugs that cause the kidneys to remove glucose through urine has been